KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Invested Capital (2019 - 2025)

Royalty Pharma's Invested Capital history spans 7 years, with the latest figure at $18.7 billion for Q4 2025.

  • For Q4 2025, Invested Capital rose 3.96% year-over-year to $18.7 billion; the TTM value through Dec 2025 reached $18.7 billion, up 3.96%, while the annual FY2025 figure was $18.7 billion, 3.96% up from the prior year.
  • Invested Capital for Q4 2025 was $18.7 billion at Royalty Pharma, up from $18.6 billion in the prior quarter.
  • Across five years, Invested Capital topped out at $18.7 billion in Q4 2025 and bottomed at $15.7 billion in Q1 2021.
  • The 5-year median for Invested Capital is $17.3 billion (2021), against an average of $17.1 billion.
  • The largest annual shift saw Invested Capital soared 118.61% in 2021 before it fell 10.33% in 2023.
  • A 5-year view of Invested Capital shows it stood at $17.3 billion in 2021, then decreased by 4.05% to $16.6 billion in 2022, then decreased by 2.54% to $16.2 billion in 2023, then grew by 10.7% to $18.0 billion in 2024, then grew by 3.96% to $18.7 billion in 2025.
  • Per Business Quant, the three most recent readings for RPRX's Invested Capital are $18.7 billion (Q4 2025), $18.6 billion (Q3 2025), and $17.5 billion (Q2 2025).